China Cosmetics Market Report, 2010-2011 | ReportsnReports

2012-02-11
Published : Feb-2012
In 2010, Chinese skincare market size reached RMB64.2 billion, turning into the largest cosmetics market segment. In the same year, retail sales of top ten skincare brands accounted for 38% of the entire skincare market, of which, 80% were foreign brands, while domestic brands merely referred to Chcedo and Herborist. Since 2012, China has cut import tariffs for imported skincare products, which favors multinational cosmetics manufacturers.
In 2010, Maybelline enjoyed a 10.8% share of Chinese make-up market, a drop from 20% in 2006, mainly because China’s local cosmetics brands such as Carslan and Mao Geping have been to some extent competitive with consistent innovation in product, packaging, etc.
As an emerging market segment in recent years, men’s skincare market in China reached RMB4 billion in 2010, with industry growth rate at 40% or so, far higher than that of women’s.
Request a Sample for or Inquire before buying the report@

CHINA COSMETICS MARKET

 
China Cosmetics Market Report, 2010-2011 by ResearchInChina mainly covers the following s:
  • Industry Research: primarily includes scale, competition pattern & features, import & export of China cosmetics industry.
  • Channel Analysis:chiefly studies development status, characteristics and trends of department store channel, supermarket, specialty store, online, direct selling, etc.
  • Market Segment: covers market status & size, competition features, key players and development trends of five market segments, i.e. skin care, make-ups, perfume, men’s cosmetics as well as cosmeceuticals.
  • Major Companies:? research on 19 major cosmetics enterprises in the Chinese market, such as L’Oréal and Shanghai Jahwa.
  • As the world’s largest cosmetics corporation, L’Oréal realized sales of €19.5 billion in 2010, with 23 international brands outnumbering €50 million. In November 2011, it invested RMB200 million for construction expansion of Tianmei Plant in Yichang city, China, which will achieve capacity of 250 million pieces per year by then to become L’Oréal’s largest make-up production base in Asia.
Major points covered in Table of Contents of this report include:
  • Overview
  •  Industry Status
  • Channel Analysis
  • Market Segments
  • Other Emerging Market Segments
  • Multinational Companies
  • Chinese Companies
Explore Comprehensive list of more than Tables & Figures available in the report @ http://www.reportsnreports.com/reports/146691-china-cosmetics-market-report-2010-2011.html
Report Details :
Published:  February 2012
No. of Pages:
Price:     Single User License – US $ 2000
Corporate User License – US $ 2900
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019" provides an overview of Clostridium difficile Infections (Clostridium difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium difficile Infections (Clostridium difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and s......
$2500

Cystinosis Global Clinical Trials Review, H1, 2019

Cystinosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cystinosis Global Clinical Trials Review, H1, 2019" provides an overview of Cystinosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystinosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are ......
$2500

Community-Acquired Infections Global Clinical Trials Review, H1, 2019

Community-Acquired Infections Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Community-Acquired Infections Global Clinical Trials Review, H1, 2019" provides an overview of Community-Acquired Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprie......
$2500

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2019

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global......
$2500

Corneal Neovascularization Global Clinical Trials Review, H1, 2019

Corneal Neovascularization Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Corneal Neovascularization Global Clinical Trials Review, H1, 2019" provides an overview of Corneal Neovascularization clinical trials scenario. This report provides top line data relating to the clinical trials on Corneal Neovascularization. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Clostridium Infections Global Clinical Trials Review, H1, 2019

Clostridium Infections Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Clostridium Infections Global Clinical Trials Review, H1, 2019" provides an overview of Clostridium Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy